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Abstract
Introduction The aim was to assess the value of magnetic
resonance mammography (MRM) in the detection of recurrent
breast cancer on the prior lumpectomy site in patients with
previous conservative surgery and radiotherapy.
Methods Between April 1999 and July 2003, 93 consecutive
patients with breast cancer treated with conservative surgery
and radiotherapy underwent MRM, when a malignant lesion on
the site of lumpectomy was suspected by ultrasound and/or
mammography. MRM scans were evaluated by morphological
and dynamic characteristics. MRM diagnosis was compared
with histology or with a 36-month imaging follow-up. Enhancing
areas independent of the prior lumpectomy site, incidentally
detected during the MRM, were also evaluated.
Results MRM findings were compared with histology in 29
patients and with a 36-month follow-up in 64 patients. MRM
showed 90% sensitivity, 91.6% specificity, 56.3% positive
predictive value and 98.7% negative predictive value for
detection of recurrence on the surgical scar. MRM detected 13
lesions remote from the scar. The overall sensitivity, specificity,
positive predictive value and negative predictive value of MRM
for detection of breast malignancy were 93.8%, 90%, 62.5%
and 98.8%, respectively.
Conclusion MRM is a sensitive method to differentiate
recurrence from post-treatment changes at the prior
lumpectomy site after conservative surgery and radiation
therapy. The high negative predictive value of this technique can
avoid unnecessary biopsies or surgical treatments.
Introduction
Recurrence of breast cancer lesions on the surgical scar after
conservative surgery and radiation therapy have been reported
to occur in at least 1–2% of cases per year [1,2]. The proper
follow-up of these patients usually includes periodic clinical
examination, mammography and ultrasonography [3]. Detec-
tion of recurrence on the prior lumpectomy site still represents
a challenge because of changes in breast tissue after treat-
ment. Clinical examination, mammography or ultrasonography
can raise a suspicion but an additional evaluation is frequently
mandatory to avoid unnecessary biopsy or surgery.
Several recent studies have shown the important role of breast
magnetic resonance imaging (MRI) imaging for detection of
recurrent lesions in patients treated with conservative surgery
(quadrantectomy) and radiation therapy [3-5]. Magnetic reso-
nance mammography (MRM) has high sensitivity, high specif-
icity and high accuracy in differentiating physiologic changes
of the scar from tumoral tissue [3,6-10]. MRM multifactorial
evaluation, based on both morphological features and time–
signal intensity curves of enhancing lesions, is related to sig-
nificantly higher sensitivity and higher specificity than evalua-
tion protocols based only on one morphological or enhancing
feature [1].
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To the best of our knowledge, no specific data are available on
the accuracy of MRM to differentiate recurrent lesions from
normal changes of the surgical scar at the site of prior lumpec-
tomy when a multifactorial MRM evaluation protocol is used to
classify enhancing lesions.
This study was designed to determine whether MRM, per-
formed with a multifactorial evaluation of enhancing lesions,
improves the accuracy of diagnosis of recurrence on the sur-
gical scar in patients who underwent quadrantectomy and
local radiation therapy. Furthermore, the overall accuracy of
contrast-enhanced MRM for the detection of suspicious
enhancing lesions, even when not closely related to the surgi-
cal scar, has also been assessed in the series reported.
Materials and methods
Patients
The study cohort comprised 93 female patients who under-
went breast MRI examination between April 1999 and July
2003 for suspected recurrence on the site of conservative sur-
gery (quadrantectomy) for breast cancer, at least 6 months
after the end of radiation therapy.
All patients underwent a yearly breast evaluation, performed by
the breast radiologist with mammography, associated or not
with an ultrasound examination, according to the characteris-
tics of the breast tissue density, and underwent a clinical
examination. The clinical examination routinely performed by
the breast radiologists after the evaluation of mammographic
scans, matched in the same report of mammography, and was
also used to decide the level of suspicion.
Recurrence was suspected either by ultrasound or by mam-
mography, or by both examinations. When a malignant lesion
on the surgical scar was suspected (ultrasound and/or mam-
mographic Breast Imaging Reporting and Data System (BI-
RADS) III or BI-RADS IV), the patient underwent a contrast-
enhanced breast magnetic resonance mammography (MRM),
after signing a proper informed consent and after exclusion of
contraindications to exposure to magnetic fields.
Magnetic resonance mammography technique
All MRM examinations were performed on a Signa Horizon LX
(GE Medical Systems, Milwaukee, WI, USA), with a field
strength of 1 T. The entire breast was scanned with a two-
channel, phased-array, bilateral dedicated coil and the follow-
ing parameters: Repetition Time = 7 ms, Echo Time = 1.6 ms,
flip angle = 10°, TI = 25 ms, receiver bandwidth = 32 kHz,
Number of Excitations = 1, matrix = 320 × 320, Field of View
= 36 × 18 cm2. The slice thickness was chosen between 2
mm and 3 mm, depending on the breast size, in order to main-
tain each sequence time within 90 s.
Coronal T1-weighted, fat-suppressed (spectral inversion at
lipid) FSPGR 3D sequences were acquired once before and
five times after intravenous contrast injection (Gadopentetate
dimeglumine, 0.2 mmol/kg; flow rate = 2 ml/s). The acquisition
of dynamic images started 10 s after the contrast injection.
To determine the contrast medium uptake, baseline images
were subtracted from images obtained after contrast medium
injection. All dynamic images were sent to a diagnostic work-
station (Advantage Window 4.2; GE Medical Systems, Mil-
waukee, WI) where the maximum intensity projection and the
multiplanar reformation were obtained.
Evaluation of magnetic resonance images and 
classification of lesions
One senior radiologist, aware of the time of surgery and the
location of the primary breast cancer, and of the mammo-
graphic and ultrasonographic findings, reviewed each MRM
examination on a diagnostic workstation.
Each lesion was retrospectively reviewed and classified by the
reader according to a multifactorial evaluation protocol for
enhancing lesions connected or not to the surgical scar. Mor-
phological features and time–signal intensity curves of
enhancing lesions were classified according to the Fischer
multifactorial evaluation [1] to differentiate malignant lesions
and benign lesions.
The morphological features evaluated and graded were form,
margins and enhanced pattern. Form was considered suspi-
cious for malignancy when it was branching or spiculated,
whereas it was considered benign when it was rounded. Mar-
gins were considered suspicious for malignancy if indistinct,
while they were considered benign if well defined. The
enhancing pattern was suspicious for malignancy if it was
inhomogeneous or ring shaped, whereas it was considered
benign if it was homogeneous. Lesions were accordingly
graded on a one-point scale for form and for margins (0 =
benign, 1 = malignant), and on a two-point scale for enhancing
patterns (0 = benign, 1 = suspicious, 2 = malignant).
According to the same classification of Fischer and colleagues
[1], the dynamic course of enhancement was considered sus-
picious for malignancy if there was an initial strong increase
and a postinitial washout, while a moderate initial increase and
a postinitial plateau were considered benign. Accordingly, a
two-point scoring scale system was used both for the initial
increase of enhancement (0 = enhancement <50%, 1 = 50–
100% enhancement, 2 = enhancement >100%) and for the
postinitial enhancement (0 = steady increase, 1 = plateau, 2 =
washout).
Using this multifactorial evaluation protocol, the overall maxi-
mum score achievable is 8: a total score lower than 3 points
indicated benign lesions, whereas a total score higher than 4
points indicated malignant lesions.Available online http://breast-cancer-research.com/content/8/5/R53
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The American College of Radiology recently introduced a clas-
sification for lesions detected by MRM (adapted from the
mammographic BI-RADS classification) [11] in five classes:
BI-RADS I = negative finding, BI-RADS II = benign finding, BI-
RADS III = probably benign finding, BI-RADS IV = suspicious
finding, and BI-RADS V = a finding highly suggestive of
malignancy.
The Fischer score was accordingly converted into the MRM-
BI-RADS score of the American College of Radiology, as fol-
lows: Fischer 0, 1 = BI-RADS I; Fischer 2 = BI-RADS II;
Fischer 3 = BI-RADS III; Fischer 4 and Fischer 5 = BI-RADS
IV; Fischer 6, Fischer 7 and Fischer 8 = BI-RADS V.
MRI findings were compared either with histological findings,
if the patient underwent biopsy or surgery, or with a 36-month
follow-up with the usual imaging modalities (ultrasound and/or
mammography), if the patient did not undergo any biopsy or
surgery.
Statistical analysis
True-positive, true-negative, false-positive and false-negative
cases were recorded as follows. True-positive cases were
patients with histological signs of disease within 3 months
after the MRM indicating the lesion as suspicious for recur-
rence. True-negative cases were patients with negative find-
ings at MRM who had negative findings at ultrasonography
and/or mammography during the following 36-month follow-
up. False-positive cases were patients who underwent biopsy
or surgery because MRM indicated an enhancing lesion as
suspicious for malignancy but histological findings and follow-
up examinations were negative for malignancies. False-nega-
tive cases were patients who underwent biopsy or surgery
within 3 months after a negative MRM, because of clinical,
ultrasound or mammographic findings suspicious for recur-
rence. These patients were considered false negative at MRM
if histological examination demonstrated the presence of
cancer.
The sensitivity, specificity, positive predictive value and nega-
tive predictive value and the accuracy of MRM in the detection
of recurrent disease on the surgical scar were calculated. The
same values, with 95% confidence intervals relating to the
sensitivity and specificity, were calculated for the lesions
detected in areas not related to the scar, in order to define the
overall accuracy of MRM in the detection of new breast cancer
lesions.
Results
Ninety-three patients (mean age, 53.3 years; range, 40–72
years) were evaluated in the present study: 40 patients had
conservative surgery on the right breast, and 53 patients had
conservative surgery on the left breast. Follow-up evaluation
after surgery included mammography for all 93 patients and
ultrasound for 74 patients. Recurrence was suspected by
mammography in 27 patients (15 patients graded as mammo-
graphic BI-RADS III, 12 patients graded as BI-RADS IV), by
ultrasound in 58 patients (30 patients graded as US BI-RADS
III, 28 patients graded as BI-RADS IV), and by both examina-
tions in eight patients (one patient graded as both mammo-
graphic and ultrasound BI-RADS III, two patients graded as
ultrasound BI-RADS III and mammographic BI-RADS IV, three
patients graded as ultrasound BI-RADS IV and mammo-
graphic BI-RADS III, two patients graded as both ultrasound
and mammographic BI-RADS IV).
The mean time of follow-up after MRM, performed with mam-
mography, ultrasonography or both examinations, was 36
months (range, 12–48 months). The mean age of patients at
the time of new diagnosis was 52 years.
MRM findings were confirmed by histological findings in 29
patients and by follow-up imaging modalities (ultrasound and/
or mammography) in 64 patients.
The 93 lesions studied by MRM on the surgical scar, evaluated
according to the Fischer criteria, included 59 lesions graded
as Fischer 0, two lesions graded as Fischer 1, eight lesions
graded as Fischer 2, eight lesions graded as Fischer 3, 12
lesions graded as Fischer 4, no lesions graded as Fischer 5,
four lesions graded as Fischer 6, and no lesions graded as
Fischer 7 and Fischer 8. The same lesions subsequently clas-
sified into the magnetic resonance BI-RADS classification
were: 61 lesions graded as BI-RADS I, eight lesions graded as
BI-RADS II, eight lesions graded as BI-RADS III, 12 lesions
graded as BI-RADS IV, and four lesions graded as BI-RADS V
(Table 1).
In the evaluation of enhancing lesions on the surgical scar,
nine lesions were true-positive cases. All of these lesions were
confirmed positive by histological examination. In these cases,
malignancy was suspected by ultrasound alone in five cases
(three cases of BI-RADS III, two cases of BI-RADS IV), by
mammography alone in two cases (both graded as mammo-
graphic BI-RADS IV), and by both examinations in two cases
(one case graded as mammographic BI-RADS IV and ultra-
sound BI-RADS III, one case graded as both mammographic
and ultrasound BI-RADS IV). Histological proof of malignancy
was obtained with a vacuum-assisted breast biopsy in four
patients, with a tru-cut biopsy in three cases, with fine-needle
aspiration cytology in one case, and with fine-needle aspiration
cytology + tru-cut in one case. Four out of nine patients under-
went a complete mastectomy, 2/9 underwent a second con-
servative treatment (quadrantectomy), 1/9 died without
undergoing further surgery (histological confirmation of recur-
rence came from biopsy), and the remaining 2/9 underwent
surgery in other institutions – we received the pathological
report without a detailed description of the type of surgery.
Histological types of the true-positive cases were 8/9 infiltrat-
ing ductal carcinoma and 1/9 cribriform infiltrating carcinoma.Breast Cancer Research    Vol 8 No 5    Preda et al.
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The mean dimension of lesions was 1.96 cm (range, 0.6–3
cm). Six out of these nine lesions were graded as Fischer 4,
and the other three lesions were graded as Fischer 6 (Figure
1).
There were 76 true-negative cases: 64 patients with a nega-
tive follow-up, nine patients with negative histological findings,
and three patients with a negative histology and follow-up.
Suspicion of malignancy was raised by ultrasound in 47 cases
(25 cases graded as ultrasound BI-RADS III, 22 cases graded
as ultrasound BI-RADS IV), by mammography in 24 cases (15
cases graded as mammographic BI-RADS III, nine cases
graded as mammographic BI-RADS IV), and by both examina-
tions in five cases (one case graded as both ultrasound and
mammographic BI-RADS III, one case graded as ultrasound
BI-RADS III and mammographic BI-RADS IV, two cases
graded as ultrasound BI-RADS IV and mammographic BI-
RADS III, one case graded as both ultrasound and
mammographic BI-RADS IV). Fifty-nine of these 76 cases
were graded as Fischer 0, two lesions were graded as Fischer
1, seven lesions were graded as Fischer 2, and eight lesions
were graded as Fischer 3. Among lesions graded as Fischer 3
(probably benign), three cases underwent biopsy while five
cases underwent a 6-month MRI and a 12-month MRI as the
patients refused to undergo a biopsy.
Table 1
Magnetic resonance mammography findings
Fischer score BI-RADS score Diagnostic 
value








0I N e g a t i v e 5 9 5 9
1I N e g a t i v e 22
2 II Benign 8 7 1
3I I IP r o b a b l y  
benign
88
4 IV Suspicious 
abnormality
12 6 6
5 IV Suspicious 
abnormality
0
6 V Suggestive of 
malignancy
41 3
7 V Suggestive of 
malignancy
0
8 V Suggestive of 
malignancy
0
Classification of lesions according to the Fischer scores (0–8) and Breast Imaging Reporting and Data System (BI-RADS) scores (I–V), and the 
corresponding diagnostic value.
Figure 1
Magnetic resonance mammography 4 years after treatment for invasive ductal carcinoma Magnetic resonance mammography 4 years after treatment for invasive ductal carcinoma. This shows a 2 cm lesion (left image), with a signal–
intensity curve with early wash-in and late washout (right image) (Breast Imaging Reporting and Data System V) (invasive ductal carcinoma at 
histology).Available online http://breast-cancer-research.com/content/8/5/R53
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Seven false-positive cases were detected on the surgical scar
based on histological findings. Malignancy was suspected by
ultrasound alone in five cases (two cases graded as ultra-
sound BI-RADS III, three cases graded as ultrasound BI-
RADS IV), by mammography alone in one case (graded as BI-
RADS IV), and by both examinations in one case (graded as
mammographic BI-RADS III and ultrasound BI-RADS IV). Six
of these false-positive cases were graded at MRM as Fischer
4 (Figure 2) and one case was graded as Fischer 6. The mean
time between primary treatment (surgery and radiotherapy)
and MRM was 13 months (range, 6–24 months). Two out of
seven patients underwent the MRM less than 12 months after
treatment (6 months and 8 months, respectively).
We found only one false-negative case at MRM. The ultra-
sonographic detection of a hypoechoic inhomogeneous lesion
of 2 cm in correspondence with the surgical scar (ultrasound
BI-RADS IV) gave indication to perform MRM. The subsequent
MRM scan depicted the lesion as rounded, with regular shape
and homogeneous contrast enhancement. The time–intensity
curve showed a moderate initial increase and a steady
increase in later sequences (Figure 3). The lesion was there-
fore graded as a Fischer 2 (BI-RADS II) lesion. Despite the
negative result of the MRM, the patient underwent surgery
after 2 months because of the ultrasonographic suspicion, and
a 2 cm mucinous cancer was demonstrated on the surgical
scar. The primary malignancy in this patient was again a muci-
nous type cancer.
Thirteen lesions remote from the surgical scar of prior lumpec-
tomy were detected in seven patients. These lesions were
classified as: one Fischer 2, four Fischer 3, three Fischer 4,
two Fischer 5, two Fischer 6, and one Fischer 8. The same
lesions according to the BI-RADS classes were: 0 cases
graded as BI-RADS I, one case graded as BI-RADS II, four
cases graded as BI-RADS III, five cases graded as BI-RADS
IV, and three cases graded as BI-RADS V.
Figure 2
Magnetic resonance mammography 15 months after surgery Magnetic resonance mammography 15 months after surgery. The postcontrast image (left image) and the signal–intensity curve (right image) 
show a 2 cm lesion with inhomogeneous enhancement. (Breast Imaging Reporting and Data System IV). Histology and follow-up reported no 
malignancy.
Figure 3
Magnetic resonance mammography of 52-year-old patient who underwent quadrantectomy, adenectomy and radiotherapy for mucinous cancer Magnetic resonance mammography of 52-year-old patient who underwent quadrantectomy, adenectomy and radiotherapy for mucinous 
cancer. This shows a 3 cm rounded lesion with homogeneous contrast enhancement (left image), with the signal–intensity curve showing moderate 
initial increase and late steady increase (right image). The lesion (Breast Imaging Reporting and Data System II) was mucinous cancer.Breast Cancer Research    Vol 8 No 5    Preda et al.
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Six true-positive cases were identified, one case graded as
Fischer 4, two cases graded as Fischer 5, two cases graded
as Fischer 6, and one case graded as Fischer 8. Among these
patients, 3/6 had no malignancy on the surgical scar: one of
them underwent a controlateral quadrantectomy; the remain-
ing two patients, having enhancing lesions in a different quad-
rant, underwent a total mastectomy. Three out of six patients
had second cancer foci distant from the scar as well as on the
scar, confirmed by histology as multifocal carcinomas: in two
cases the enhancing lesions were on the same quadrant and
the patients underwent a second quadrantectomy, and in one
case the lesion was in another quadrant and the patient under-
went a total mastectomy (Figure 4). For 3/6 true-positive
cases, all graded as BI-RADS IV at mammography, second-
look ultrasound examinations were performed: in all three
cases the lesion was detected. Only in 1/3 had an ultrasound
examination been performed before the MRM, and it was con-
sidered negative.
Two false positive-cases were detected; they were graded as
Fischer 4, demonstrated as negative by histological findings
and confirmed by follow-up.
Five true-negative cases confirmed by negative findings during
the follow-up were graded as follows: one case graded as
Fischer 2, and four cases graded as Fischer 3.
During the follow-up, no enhancing lesions remote from the
scar were detected in any of the 80 patients with negative
MRM, thus confirming the absence of false-negative results.
The sensitivity, specificity, negative predictive value, positive
predictive value and accuracy of MRM for the detection of
recurrence on the surgical scar were, respectively, 90%,
91.6%, 98.7%, 56.3% and 91.4%. The overall sensitivity, spe-
cificity, negative predictive value, positive predictive value and
accuracy of MRM in the detection of breast cancer lesions
(including areas not related to the scar) were, respectively,
93.8% (95% confidence interval, 82–100%), 90% (95% con-
fidence interval, 83–96%), 98.8%, 62.5% and 90.6%.
Discussion
The long-term survival rate among women who undergo
breast-conserving surgery is the same as that among women
who undergo radical mastectomy [12]. Breast-conserving sur-
gery is therefore currently considered the treatment of choice
for women with relatively small breast cancers [12], and the
rate of recurrence reported in these patients is about 1–2%
per year [1,2]. Long-term survival of patients with new malig-
nancy after conservative treatment improves with early detec-
tion [10,13].
The diagnostic evaluation of the treated breast is unfortunately
still a challenge because post-treatment changes of breast tis-
sue can show great variability, hiding or mimicking recurrent
lesions [3,14]. Changes following breast-conserving surgery
can include hematoma, seroma, fat tissue necrosis, scar tissue
development and dystrophic calcifications [15]. Changes after
radiotherapy can include vascular dilatation, capillary damage,
microcirculatory changes and edema [15,16]. The association
of these changes after breast-conserving surgery and irradia-
tion make the interpretation of clinical examination and mam-
mography very difficult because of focal thickening, decreased
compressibility and increased density at the surgical site
[3,13].
At our institution the usual follow-up of breast cancer patients
treated with breast-conserving surgery and irradiation is based
on annual imaging evaluation performed with mammography,
completed by clinical examination and/or ultrasound examina-
tion, according to the density of the breast.
Local recurrence is the development of a tumor in the ipsilat-
eral (treated) breast that occurs after treatment of the initial
breast cancer [17]. Comparison of studies relating to the
detection of recurrence can be difficult because of differences
in the definitions of local recurrence [17]. Mammography has
limited sensitivity in these lesions [8,18], because of an
insufficient morphological distinction between therapy-
induced edema and lymphangiosis carcinomatosa or between
radially striated scar tissue and tumor recurrence [15]. This
Figure 4
Magnetic resonance mammography 2 years after therapies for invasive ductal carcinoma Magnetic resonance mammography 2 years after therapies for invasive ductal carcinoma. This shows two lesions (arrows) (Breast Imaging 
Reporting and Data System IV, V), reported by biopsy as malignant.Available online http://breast-cancer-research.com/content/8/5/R53
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lack of specificity can delay early detection and treatment of
recurrent lesions [8]. The ultrasound examination is used as a
complementary follow-up imaging modality of the treated
breast, especially in radiodense breasts. This examination
does have high sensitivity if performed at regular intervals,
because of the detection of hypoechoic nodules within fibrous
hyperechoic tissue [3]. The sensitivity of ultrasound is user
dependent, however, and it is limited when evaluating small or
noninvasive lesions, especially in fatty breasts.
For these reasons, MRM is considered a useful additional
examination in patients with suspicion of recurrence [7,8].
Progress in breast MRI has been limited by a lack of standard-
ization in the acquisition and interpretation of MRM images,
with some studies focusing on morphology (spatial resolution)
[19] and other studies stressing kinetics (temporal resolution)
[20,21].
In the present study, the multifactorial evaluation protocol pro-
posed by Fischer and colleagues [1] was used to evaluate
enhancing lesions on the site of prior lumpectomy, based both
on their morphologic and kinetic characteristics, in an attempt
to standardize their evaluation. The number of true-negative
cases confirmed by histology (12 lesions) demonstrates that
12 unnecessary biopsies could have been avoided using this
multifactorial protocol.
The dynamic enhancement pattern, combined with morphol-
ogy, on contrast-enhanced MRI of breast masses, allows
reproducible lesion characterization [22], and it is useful to dif-
ferentiate between benign and malignant lesions [21,23]. A
review of the literature has reported a sensitivity of more than
90%, and 85–100% specificity, for MRM to detect recurrence
[7,10,24-26]. In the present study MRM correctly detected 8/
9 lesions on the surgical scar, all being infiltrating carcinomas.
The sole false-negative lesion was an infiltrating mucinous car-
cinoma. The lesion showed well-defined margins, regular
shape and homogeneous contrast enhancement, with a mod-
erate initial increase and a steady increase in later sequences
(graded as Fischer 2 and BI-RADS II). Other cases of infiltrat-
ing mucinous breast cancer not detected by MRM have been
described [27,28]. The large amount of mucus slows the dif-
fusion of contrast medium through the entire tumor [27,29],
and thereby induces gradual enhancement curves [30,31].
T2-weighted images have been considered useful because of
the very high signal intensity on these sequences compared
with other histologic types [29]. In this case, the T2-weighted
sequence would probably have been helpful in detecting the
mucinous lesion. Nevertheless, this type of sequence is not
routinely performed in our institution because of the low rate of
this histological type (1–4%) [29].
MRM in the present study found seven false-positive cases,
although all examinations were performed at least 6 months
after treatment. Other studies have demonstrated difficulties in
differentiating a recurrent tumor from postoperative changes
within 6 months after surgery [32] and within 12 months after
radiation therapy [33]. In the seven false-positive cases
described herein, the mean time between treatments and
MRM was 13 months, and only in two of these cases was the
time between the end of radiotherapy and MRM shorter than
12 months (6 months and 8 months, respectively).
The high sensitivity in detection of multifocality, in particular for
lesions located far from the scar, has influenced the type of
repeat surgery (quadrantectomy versus mastectomy). These
results are comparable with other studies [9] performed on
smaller numbers of patients.
Of particular relevance is the very high negative predictive
value of MRM (98.7%), which indicates a very low likelihood of
new malignancy if MRM defines the lesion as benign. These
results suggest that lesions graded by MRM as Fischer I–II
(BI-RADS I–II) can be safely monitored with the usual yearly
follow-up. A repeat MRM examination after 6 months is recom-
mended for lesions graded as Fischer III (BI-RADS III), if there
is no clinical suspicion of recurrence before 6 months. For
lesions graded higher than Fischer IV (BI-RADS IV–V), further
cytological or histological evaluation is mandatory.
One limitation of this study is the lack of in situ ductal carci-
noma in our series. Ductal carcinoma in situ is considered one
of the most common causes of false-negative results at MRM
[34], and this can decrease the diagnostic accuracy of the
technique. In the present series we found no ductal carcinoma
in situ, and this does probably justify the 93.8% overall sensi-
tivity with only one false-negative case. Another limitation was
that imaging examinations were evaluated by a single reviewer.
We therefore did not assess the interobserver variability in the
use of this multifactorial protocol.
Conclusion
This series demonstrates the high sensitivity and high specifi-
city of MRM in confirming or excluding recurrence at the prior
lumpectomy site, after conservative surgery and radiation ther-
apy, when recurrence was already suspected either by mam-
mography (including the associated clinical examination) or by
ultrasonography. MRM has shown an overall high negative
predictive value (98.8%) in the detection of breast cancer,
including lesions not related to the surgical scar.
Despite the high accuracy of MRM in detecting recurrence on
the site of lumpectomy, its cost and low availability limit its use
for the routine follow-up of treated patients. In some
conditions, however, as in the presence of radiodense breasts
and/or structural post-treatment changes, MRM represents an
important diagnostic modality in support of the other
traditional imaging modalities, and it can be considered con-
clusive when showing negative findings.Breast Cancer Research    Vol 8 No 5    Preda et al.
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